Overview
Chronic depression, also known as persistent depressive disorder, is characterized by a depressed mood that lasts for at least two years, often accompanied by loss of interest, fatigue, and impaired functioning 1.Diagnosis
Persistent depressed mood most of the day, nearly every day for at least two years 1.
Presence of at least two additional symptoms: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self-esteem, poor concentration, or feelings of hopelessness 1.
Symptoms cause significant distress or impairment in social, occupational, or other important areas of functioning 1.
Exclusion of other psychiatric disorders that might explain the presentation 1.Management
First-line treatments: Cognitive Behavioral Therapy (CBT) and Interpersonal Psychotherapy (IPT) are recommended psychotherapies 1.
Pharmacotherapy: Antidepressants, particularly Selective Serotonin Reuptake Inhibitors (SSRIs) such as sertraline or escitalopram, are commonly used 1.
Adjunctive treatments: Mindfulness-based interventions and exercise programs may be beneficial adjuncts 1.Special Populations
Elderly: Middle-aged and older women with disabilities may require tailored interventions addressing both pain and depressive symptoms, such as the PRIME intervention 1.
Comorbidities: Specific interventions targeting comorbid conditions like chronic pain are crucial for improved outcomes in this population 1.Key Recommendations
Evaluate and address comorbid chronic pain in middle-aged and older women with depressive symptoms to enhance treatment efficacy (Evidence: Moderate 1).
Consider tailored psychotherapeutic interventions like CBT or IPT for managing chronic depression, especially in vulnerable populations 1.
Utilize SSRIs as first-line pharmacotherapy, with careful monitoring for efficacy and side effects, particularly in elderly patients 1.References
1 Taylor JL, Clair CA, Atkins S, Wang C, Booth A, Reid MC et al.. A protocol for a wait list control trial of an intervention to improve pain and depressive symptoms among middle-aged and older women living with disabilities. Contemporary clinical trials 2025. link